Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2013-001416-30-ES
EUCTR2013-001416-30-ES
Active, not recruiting
Phase 1

?Multicenter study of a single arm to evaluate the safety of eribulin in 3rd line chemotherapy for patients with HER2-negative metastatic or locally advanced previously treated with anthracyclines and taxanes: Onsite Study - ONCOSUR-2012-02

Fundación Oncosur0 sites60 target enrollmentSeptember 5, 2013
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions-MedDRA version: 14.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
DrugsHALAVEN 0,44 mg/ml solución inyectable

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
-
Sponsor
Fundación Oncosur
Enrollment
60
Status
Active, not recruiting
Last Updated
9 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 5, 2013
End Date
TBD
Last Updated
9 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Fundación Oncosur

Eligibility Criteria

Inclusion Criteria

  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 60
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range 60

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 1
To evaluate the safety tolerability and performance of the liver assist device (EBDLR System) in patients suffering from Acute Liver FailureHealth Condition 1: K720- Acute and subacute hepatic failure
CTRI/2024/02/062612Ykrita Life sciences Pvt Ltd.
Completed
Not Applicable
Reduction of contrast induced nephropathy (CIN) in patients requiring a percutaneous coronary intervention procedure and have chronic renal failure.Cardiovascular disease in patients with chronic kidney disease.Renal and Urogenital - Kidney diseaseCardiovascular - Diseases of the vasculature and circulation including the lymphatic system
ACTRN12612000238875Osprey Medical Pty Ltd42
Active, not recruiting
Phase 1
A clinical study, conducted in several sites in Belgium, investigating the administration at patient's home of the new subcutaneous formulation of the drug trastuzumab for treating patients suffering from a type of breast cancer at early stage, called HER2-positive early breast cancer.TO INVESTIGATE THE AT HOME ADMINISTRTATION OF TRASTUZUMAB SUBCUTANEOUS VIAL FOR THE TREATMENT OF PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER.Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2013-000123-13-BEV ROCHE SA100
Recruiting
Phase 3
A study to investigate the pharmacokinetics and safety of dupilumab in participants >=2 years to < 12 years of age with uncontrolled chronic spontaneous urticaria (CSU) or chronic inducible cold urticaria (CICU)
JPRN-jRCT2031220733Tanaka Tomoyuki24
Completed
Not Applicable
Prospective Multi-Center, Single Arm Study of the Shockwave Coronary Rx Lithoplasty® System in Coronary Arteriesarterial stenosisstenotic coronary arteries10011082
NL-OMON43455Shockwave Medical Inc.15